JUPITER NEUROSCIENCES, INC.·4

Jul 13, 4:00 PM ET

Kampf Julie B. 4

Research Summary

AI-generated summary

Updated

Jupiter Neurosciences (JUNS) Director Julie Kampf Receives 82,875 Shares

What Happened
Director Julie B. Kampf reported the conversion/vesting of 82,875 restricted stock units (RSUs) into common shares on June 2, 2025. The Form 4 shows an "acquired" entry for 82,875 shares (conversion) and a matching "disposed" entry at $0.00, which reflects the derivative-to-stock conversion — not a cash sale or market trade.

Key Details

  • Transaction date: 2025-06-02. Filing date: 2026-07-13 (late filing — see below).
  • Quantity: 82,875 shares converted/received. Reported price for the disposed entry: $0.00 (no cash sale). Transaction code: M (exercise/conversion of derivative).
  • Shares owned after transaction: not specified in the provided filing excerpt.
  • Footnotes: F1 — RSUs convert one-for-one into common stock. F2 — These RSUs vested upon expiration of the issuer’s IPO lock‑up period.
  • Timeliness: The Form 4 was filed over a year after the reported transaction date, which is a late disclosure and reduces the timeliness/transparency of the insider report.

Context
This was a routine vesting/conversion of previously granted RSUs into common shares, not a purchase or an open‑market sale. No cash was reported as received, and there’s no indication the shares were immediately sold. Such vested awards are common following IPO lock-up expirations and do not by themselves signal buying or selling intent.